46 citations
,
June 2015 in “Journal of Investigative Dermatology” Androgen receptor activity blocks Wnt/β-catenin signaling, affecting hair growth and skin cell balance.
26 citations
,
September 2024 in “Perspectives in Clinical Research” Drug repurposing offers faster, cheaper drug development but faces challenges like safety, ethics, and funding.
April 2017 in “Journal of Investigative Dermatology” SB414 may be an effective treatment for atopic dermatitis by reducing swelling and bacterial infection.
October 2025 in “EMJ Dermatology” GLP-1RA therapy may increase the risk of hair loss.
25 citations
,
December 2001 in “Expert Opinion on Pharmacotherapy” Potassium channel openers show promise for treating heart disease and other conditions, but more research is needed to fully understand their effects and safety.
9 citations
,
December 2023 in “Journal of Neuroimmune Pharmacology” NDP-MSH protects brain cells and reduces inflammation in Parkinson's disease by activating MC1R and involving Tregs.
10 citations
,
December 2005 in “Aktuelle Dermatologie” Alfatradiol (0.025%) is an effective and safe treatment for hair loss in both women and men.
January 2002 in “映像情報メディア学会技術報告” Some prostate cancers have gene changes that may affect treatment with certain drugs.
April 2024 in “The Journal of urology/The journal of urology” SRD5A2 methylation in blood can predict how well someone will respond to finasteride treatment.
5 citations
,
May 2022 in “Clinical & Experimental Metastasis” Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.
19 citations
,
October 2018 in “PLOS ONE” 5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.
17 citations
,
November 2017 in “Experimental physiology” Breathing in newborn rats is affected differently by hormones based on their sex.
November 2024 in “Circulation” GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.
135 citations
,
March 2000 in “Journal of Biological Chemistry” Agouti and AGRP affect pigmentation and obesity, with implications for metabolic disorders.
January 2012 in “Methods in pharmacology and toxicology” TRPV3 could be a target for treating pain, skin disorders, and hair problems, but more research is needed to create effective drugs.
52 citations
,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
147 citations
,
October 2021 in “Cancer Communications” RC48 shows promise for treating certain advanced cancers, but more research is needed.
January 2017 in “Brazilian Journal of Pharmaceutical Sciences” Arteannuin might work against cancer and Alzheimer's by targeting neprilysin.
19 citations
,
June 2010 in “Journal of acupuncture and meridian studies” A plant extract was found to effectively block an enzyme related to male hormone-related diseases.
July 2024 in “Journal of Investigative Dermatology” JW0061 may be a new treatment for hair loss by promoting hair growth through WNT signaling.
22 citations
,
January 2001 in “Chemical & Pharmaceutical Bulletin” Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.
June 2026 in “Frontiers in Nutrition” January 2026 in “Journal of Dermatological Science” DcR3 helps heal wounds and regrow hair by changing macrophages to a repair-focused type.
47 citations
,
November 1982 in “Journal of Cardiovascular Pharmacology” Nitrendipine and nifedipine effectively block muscle contractions, while papaverine relaxes them and minoxidil needs high amounts to work.
January 2015 in “프로그램북(구 초록집)” Two patients with stubborn hair loss grew hair after PDRN injections.
11 citations
,
July 1998 in “Journal of Investigative Dermatology” β-estradiol slows hair growth in mice.
72 citations
,
January 2003 in “American Journal of Pathology” A protein called CBP is found in prostate cancer and can increase the effectiveness of certain prostate cancer treatments.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
May 2012 in “Journal of Clinical Oncology” Taking 5-alpha reductase inhibitors might be linked to breast cancer in men.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.